3 of the best ASX 200 shares to buy in August

Looking for big returns? Brokers think these shares could provide them.

| More on:
a man with a wide, eager smile on his face holds up three fingers.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Brokers have been running the rule over a large number of ASX 200 shares in recent weeks.

Three shares that are highly rated and feature on best idea lists are named below. Here's why they could be great options:

Neuren Pharmaceuticals Ltd (ASX: NEU)

Bell Potter thinks that Neuren Pharmaceuticals could be an ASX 200 share to buy this month.

It is a growing biotechnology company that is busy developing treatments for rare diseases of the central nervous system.

The broker is feeling positive about the company's NNZ-2591 product, which has a significant market opportunity. It explains:

In the last six months, NNZ-2591 reported highly encouraging Phase 2 data in two rare diseases. NEU will once again have first-to-market opportunities in these two rare diseases, assuming future Phase 3 trials are successful. While short-term news will continue to be impacted by Acadia's commercialisation of NEU's first drug, called Daybue, we maintain our BUY recommendation for investors who have a longer 2 to 3-year investment horizon.

Bell Potter has a buy rating and $28.00 price target on its shares. This suggests that upside of 50% is possible for investors from current levels.

Perpetual Ltd (ASX: PPT)

Analysts at Bell Potter are also feeling bullish about Perpetual and see it as an ASX 200 share to buy in August.

The broker believes that the market is undervaluing the remaining business following the sale of its Corporate Trust and Wealth management businesses to private equity firm KKR. It said:

Perpetual announced a disposal of the Corporate Trust (CT) and Wealth Management (WM) businesses to KKR for $2.175bn. This price was ahead of our expectations ($1.5-1.9bn), and should result in a cash payment to shareholders of between $804m-1,104m or $6.95- 9.55 per share, dependent upon the assumptions, particularly tax and deal costs. We estimate the residual asset management business is being valued at between $1.3-1.6bn or between 3.5x-5.5x EBITDA. We believe this is too low for an international asset manager. Valuing the residual asset management business on 6.3x FY25 would imply a value of $2.1bn or $18.17/per share.

Bell Potter has a buy rating and $27.60 price target on its shares. Based on its current share price, this implies potential upside of 28% for investors.

Woodside Energy Group Ltd (ASX: WDS)

A final ASX 200 share that has been tipped as a top buy is Woodside Energy.

Morgans is a big fan of the energy giant and believes its shares are undervalued at current levels following a pullback. As a result, it thinks now is an opportune time to invest. The broker said:

A tier 1 upstream oil and gas operator with high-quality earnings that we see as likely to continue pursuing an opportunistic acquisition strategy. WDS's share price has been under pressure in recent months from a combination of oil price volatility and approval issues at Scarborough, its key offshore growth project. With both of those factors now having moderated, with the pullback in oil prices moderating and work at Scarborough back underway, we see now as a good time to add to positions. Increasing our conviction in our call is the progress WDS is making through the current capex phase, while maintaining a healthy balance sheet and healthy dividend profile.

Morgans has an add rating and $35.00 price target. This suggests that upside of 27% is possible from current levels.

Motley Fool contributor James Mickleboro has positions in Woodside Energy Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Guess which beaten down ASX share is rocketing 11% today

Why are investors buying this beaten down stock? Let's find out.

Read more »

Broker working with share prices on computers.
Broker Notes

These 3 ASX All Ords stocks just got sizeable broker upgrades

Top brokers expect strong performance from these ASX All Ords stocks.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Morgans says these ASX 200 stocks can rise 30%

Big returns could be on the cards for buyers of these shares.

Read more »

Successful group of people applauding in a business meeting and looking very happy.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A group of stockbrokers sit in a room with several computer screens in front of them as they discuss the Zip share price and Zip's merger with Sezzle
Broker Notes

Here are the latest broker rating changes on 3 prominent ASX shares

Brokers have delivered a mixed bag this week.

Read more »

Two people climb to the summit and raise their arms in success as the sun rises brightly over the mountains.
Financial Shares

'Strong momentum': 2 ASX financial shares backed by top fundie for 2025

ASX financial shares had a strong trading session on Tuesday with several new price records set.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Broker Notes

The best Australian shares to buy with $7,000 right now

Analysts think these shares could give you a good return on investment.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Broker Notes

Top broker says buy ResMed and this ASX 200 share

Ord Minnett was impressed with their quarterly updates from last month.

Read more »